Continuation Rate of Atypical Antipsychotics After Discharge When Initiated in the Intensive Care Unit

Abstract

Purpose:

The frequency with which atypical antipsychotics initiated in the intensive care unit (ICU) is unknown. While there is lack of evidence to support the exact duration of treatment, antipsychotics should not be continued chronically for agitation and psychosis related to critical illness. The objective of this study was to determine whether atypical antipsychotics initiated in the ICU at a large tertiary academic medical center were continued after hospital discharge. Safety outcomes were also assessed.

Materials:

A total of 1023 patients who received atypical antipsychotics during ICU stay were identified. Patients were assessed in a pseudo-randomized fashion until a sample of 191 patients was reached. After review of the exclusion criteria, the final study population was 100 patients. When antipsychotics were discontinued, progress notes were reviewed to identify the reason for discontinuation. Safety outcomes were assessed based on physician documentation in the medical charts.

Results:

Atypical antipsychotics were continued in 23% of patients. Atypical antipsychotics were discontinued in 1 patient due to QTc prolongation.

Conclusions:

Atypical antipsychotics initiated in the ICU are frequently continued after hospital discharge. Given the known risks associated with extended therapy, initiatives are needed to prevent inappropriate continuation.

Keywords

atypical antipsychotics inappropriate prescribing intensive care unit medication reconciliation medication safety

Get full access to this article

View all access options for this article.

References

Abilify® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012.

Zyprexa® [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.

Seroquel® [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011.

Risperdal® [package insert]. Titusville, NJ: Janssen, LP; 2011.

Geodon® [package insert]. New York, NY: Pfizer Inc; 2009.

Fountoulakis

Nimatoudis

Iacovides

. Off label indication for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004;3(4):1–10.

Brooke

Wiersgalls

Salzman

. Atypical uses of atypical antipsychotics. Harvard Rev of Psychiatry. 2005;13(6):317–339.

Devlin

Bhat

Roberts

. Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. Ann Pharmacother. 2011;45(10):1217–1229.

Devlin

Skrobik

. Antipsychotics for the prevention and treatment of delirium in the intensive care unit: what is their role? Harv Rev Psychiatry. 2011;19(2):59–67.

10.

Hipp

Ely

. Pharmacological and nonpharmacological management of delirium in critically ill patients. Neurotherapeutics. 2012;9(1):158–175.

11.

Jacobi

Fraser

Coursin

. clinical practice guidelines for the sustained use of sedatives and analgesics in the critically care adult. Crit Care Med. 2002;30(1):119–141.

12.

Devlin

Al-Qadheeb

Skrobik

. Pharmacologic prevention and treatment of delirium in critically ill and non-critically ill hospitalized patients: a review of data from prospective, randomized studies. Best Pract Res ClinAnaesthesiol. 2012;26(3):289–309.

13.

Devlin

Roberts

Fong

. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010;38(2):419–427.

14.

Pandharipande

Girard

Jackson

. Long term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306–1316.

15.

Alexander

Gallagher

Mascola

.Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–184.

16.

Gilchrist

Asoh

Greenberg

. Atypical antipsychotics for the treatment of ICU delirium. J Intensive Care Med. 2012;27(6):354–361.

17.

Haddad

Hellewell

JSE

Wieck

. Antipsychotic-induced hyperprolactenemia: a series of illustrative case reports. J Psychopharmacol. 2001:15(4):293–295.

18.

Lindenmayer

Czobor

Volavka

. Changes in glucose and cholesterol control levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(10):290–296.

19.

Herrmann

Mamdani

Lanctôt

. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113–1115.

20.

Schneider

Dagerman

Insel

. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.

21.

FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Web site. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094303.htm. Accessed April 14, 2016.

22.

Pisani

Inouye

McNicoll

. Screening for preexisting cognitive impairment in older intensive care unit patients: use of proxy assessment. J Am Geriatr Soc. 2003;51(5):689–693.

23.

Cohen Michael

. Medication Errors. 2nd edition. Washington, D.C.: American Pharmaceutical Association; 2007:55–66.

24.

Fijn

Van den Bemt

Chow

. Hospital prescribing errors: epidemiological assessment of predictors. J Clin Pharmacol. 2002;53(3):326–331.

25.

Feely

Chan

McManus

. The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics. 1999:16(2):175–181.

26.

Van Eijk

van Marum

Klijn

. Comparison of delirium assessment tools in a mixed intensive care unit. Crit Care Med. 2009;37(6):1881–1885.

27.

Spronk

Riekerk

Hofhuis

. Occurrence of delirium is severely underestimated in the ICU during daily care. Intensive Care Med. 2009;35(7):1276–1280.

28.

Devlin

Fong

Schumaker

. Use of a validated delirium assessment tool improves the ability of physicians to identify delirium in medical intensive care unit patients. Crit Care Med. 2007;35(12):2721–2724.

29.

Beach

Celano

Noseworthy

. QTc Prolongation, Torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.

30.

Vieweg

. New generation atypical antipsychotic drugs and QTc Interval Prolongation. Prim Care Companion J Clin Psychiatry. 2003;5(5):205–215.

31.

Reilly

Ayis

Ferrier

. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048–1052.